An Assay that Predicts In Vivo Efficacy for DNA Aptamers that Stimulate Remyelination in a Mouse Model of Multiple Sclerosis

Robin M. Heider; John A. Smestad; Hernan Nicolas Lemus; Brandon Wilbanks; Arthur E. Warrington; Justin P. Peters; Moses Rodriguez; L. James Maher

doi:10.1016/j.omtm.2018.03.005

An Assay that Predicts In Vivo Efficacy for DNA Aptamers that Stimulate Remyelination in a Mouse Model of Multiple Sclerosis

Robin M. Heider, John A. Smestad, Hernan Nicolas Lemus, Brandon Wilbanks, Arthur E. Warrington, Justin P. Peters, Moses Rodriguez, L. James Maher

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Multiple sclerosis (MS) is a debilitating disease for which regenerative therapies are sought. We have previously described human antibodies and DNA aptamer-streptavidin conjugates that promote remyelination after systemic injection into mice infected by Theiler's murine encephalomyelitis virus. Here, we report an in vitro assay of myelin binding with results that correlate with remyelination outcome in vivo, as shown for data from a set of DNA aptamer complexes of different size and formulation. This in vitro assay will be valuable for future screening of MS regenerative therapies targeting remyelination.

Original language	English (US)
Pages (from-to)	270-277
Number of pages	8
Journal	Molecular Therapy Methods and Clinical Development
Volume	9
DOIs	https://doi.org/10.1016/j.omtm.2018.03.005
State	Published - Jun 15 2018

Keywords

aptamer
multiple sclerosis
myelin
oligodendrocyte
regeneration

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology
Genetics

Access to Document

10.1016/j.omtm.2018.03.005

Cite this

@article{89099952f247413cb68e4807bd917535,

title = "An Assay that Predicts In Vivo Efficacy for DNA Aptamers that Stimulate Remyelination in a Mouse Model of Multiple Sclerosis",

abstract = "Multiple sclerosis (MS) is a debilitating disease for which regenerative therapies are sought. We have previously described human antibodies and DNA aptamer-streptavidin conjugates that promote remyelination after systemic injection into mice infected by Theiler's murine encephalomyelitis virus. Here, we report an in vitro assay of myelin binding with results that correlate with remyelination outcome in vivo, as shown for data from a set of DNA aptamer complexes of different size and formulation. This in vitro assay will be valuable for future screening of MS regenerative therapies targeting remyelination.",

keywords = "aptamer, multiple sclerosis, myelin, oligodendrocyte, regeneration",

author = "Heider, {Robin M.} and Smestad, {John A.} and Lemus, {Hernan Nicolas} and Brandon Wilbanks and Warrington, {Arthur E.} and Peters, {Justin P.} and Moses Rodriguez and Maher, {L. James}",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2018",

month = jun,

day = "15",

doi = "10.1016/j.omtm.2018.03.005",

language = "English (US)",

volume = "9",

pages = "270--277",

journal = "Molecular Therapy Methods and Clinical Development",

issn = "2329-0501",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - An Assay that Predicts In Vivo Efficacy for DNA Aptamers that Stimulate Remyelination in a Mouse Model of Multiple Sclerosis

AU - Heider, Robin M.

AU - Smestad, John A.

AU - Lemus, Hernan Nicolas

AU - Wilbanks, Brandon

AU - Warrington, Arthur E.

AU - Peters, Justin P.

AU - Rodriguez, Moses

AU - Maher, L. James

PY - 2018/6/15

Y1 - 2018/6/15

N2 - Multiple sclerosis (MS) is a debilitating disease for which regenerative therapies are sought. We have previously described human antibodies and DNA aptamer-streptavidin conjugates that promote remyelination after systemic injection into mice infected by Theiler's murine encephalomyelitis virus. Here, we report an in vitro assay of myelin binding with results that correlate with remyelination outcome in vivo, as shown for data from a set of DNA aptamer complexes of different size and formulation. This in vitro assay will be valuable for future screening of MS regenerative therapies targeting remyelination.

AB - Multiple sclerosis (MS) is a debilitating disease for which regenerative therapies are sought. We have previously described human antibodies and DNA aptamer-streptavidin conjugates that promote remyelination after systemic injection into mice infected by Theiler's murine encephalomyelitis virus. Here, we report an in vitro assay of myelin binding with results that correlate with remyelination outcome in vivo, as shown for data from a set of DNA aptamer complexes of different size and formulation. This in vitro assay will be valuable for future screening of MS regenerative therapies targeting remyelination.

KW - aptamer

KW - multiple sclerosis

KW - myelin

KW - oligodendrocyte

KW - regeneration

UR - http://www.scopus.com/inward/record.url?scp=85045699819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045699819&partnerID=8YFLogxK

U2 - 10.1016/j.omtm.2018.03.005

DO - 10.1016/j.omtm.2018.03.005

M3 - Article

AN - SCOPUS:85045699819

SN - 2329-0501

VL - 9

SP - 270

EP - 277

JO - Molecular Therapy Methods and Clinical Development

JF - Molecular Therapy Methods and Clinical Development

ER -

An Assay that Predicts In Vivo Efficacy for DNA Aptamers that Stimulate Remyelination in a Mouse Model of Multiple Sclerosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this